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factors in response to a variety of stimuli. A remarkable
newly identified regulatory function of IFN-/ is the
facilitation of expression of other IFN genes. Particular
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IFN genes, i.e., IFN- and/or IFN-4, are induced in theDivision of Biology and Medicine
first cell targets of viral infection because IRF-3, broadlyBrown University
and constitutively expressed at a low level, is activatedProvidence, Rhode Island 02912
to promote their transcription (Juang et al., 1998; Marie
et al., 1998). A consequence of expression of the first
IFN gene targets is that their products are released to
The type 1 interferons,  and  (IFN-/), are comprised act through the IFN-/ receptors and STAT1 for the
of the products of multiple (up to 12) IFN- genes and induction of IRF-7 in neighboring cells. Upon infection
a single IFN- gene. These factors use a common het- with virus, cells expressing IRF-7 are induced to express
erodimeric receptor, broadly expressed on most cells. other IFN- genes, i.e., non 4 subtypes. This positive
The major pathway of intracellular signaling used by feedback for type 1 IFN expression is in effect an IFN-
IFN-/ and their receptors accesses the tyrosine ki- / to IFN-/ induction cascade with the virus as a
nases, Jak 1 and Tyk 2, activating the signal transducer cofactor.
and activators of transcription (STAT) 1 and STAT2 to IL-12 Expression and Function
form a STAT1/STAT2 heterodimer. Other pathways, Type 1 IFN can clearly influence the expression and
however, are also induced. STAT1/STAT2 complexes function of a variety of cytokines. In contrast to the IFN-
associate with a p48 protein, identified as the interferon promotion of IL-12 expression, IFN-/ can negatively
responsive factor (IRF) 9, to form the interferon-stimu- regulate IL-12 expression. This was first demonstrated
lated gene factor-3 (ISGF-3). ISGF-3 induces transcription in the mouse in culture systems using a potent replica-
as a result of recognizing interferon stimulated response tion-independent stimulus, fixed staphylococcus aure-
elements (ISREs) in promoter regions of interferon re- ous Cowan strain (SAC), and in vivo during infections
sponsive genes (Biron and Sen, 2001). of mice with lymphocytic choriomeningitis virus (LCMV)
Although first characterized based on potent antiviral (Cousens et al., 1997). The effect requires high, but phys-
functions, IFN-/ also mediate a variety of immunoreg- iologically relevant, concentrations of IFN-/ and is
ulatory effects. The immune modulating functions sug- observed as decreases in both the inducible p40 chain
gest that type 1 IFNs may be important links between and the biologically active p70 heterodimer comprised
innate and adaptive immune responses. IFN-/ induc- of the p40 and p35 chains. The negative effect of IFN-
tion of MHC class I expression and activation of natural / on IL-12 expression has now been observed with
killer (NK) cell cytotoxicity has long been appreciated. human DCs and monocytes. In the case of DCs, addition
The last few years of research have not only advanced of IFN- inhibits the expression of IL-12 p40 in response
the characterization of these classic IFN activities but to stimulation with activated CD4 T cells (McRae et al.,
have also revealed a number of surprises concerning 1998). In the case of monocytes, cells pretreated with
other biologically important immunoregulatory func- IFN- or IFN- are inhibited in their p40 and p70 IL-12
tions. The strongest evidence is for IFN-/ enhance- responses to lipopolysaccharide (LPS) or SAC alone
ment of induction of other IFN-/ cytokines and IL-15; (Hermann et al., 1998; Karp et al., 2000). The inhibitory
the apparently contrasting inhibition of IL-12 expression effects in these systems also require relatively high con-
but induction of a high-affinity form of the IL-12 receptor; centrations of IFN-/.
the shaping of NK cell responses; the complex positive The negative regulation of IL-12 expression appears
and negative effects on IFN- expression; and effects to contradict the IFN-/ enhancing effects on expres-
sion of the heterodimeric high-affinity receptor for IL-on dendritic cell (DC) maturation and function. These
12 comprised of 1 and 2 chains. This complex isare reviewed below.
upregulated on human T cells in response to either IFN-IFN-/ Regulation of IFN-/ Expression
/ or IFN- (Gollob et al., 1997; Rogge et al., 1997,High levels of type 1 IFN are elicited during certain viral
1998). In the mouse, IFN-plays a similar role by enhanc-infections. The major pathways to IFN-/ induction
ing mRNA expression of the IL-12 receptor 2 chainhave been thought to be cytoplasmic receptors acti-
(Szabo et al., 1997). An equivalent function for IFN-/vated by the presence of viral products. The best char-
in this species is more controversial. Protein expressionacterized recognize double stranded RNA (dsRNA), not
of the IL-12R1 chain is preserved and the IL-122 chaingenerally observed in uninfected cells but often gener-
is induced on NK cells at times of high IFN-/ inductionated during viral replication. Not all viruses are good
during LCMV infections of mice (Nguyen et al., 2000).inducers of IFN-/ in infected cells, however, and other
However, IFN- fails to induce detectable upregulationknown pathways to IFN induction are linked to virus
of the IL-12R2 mRNA in mouse T cell lines (Roggebinding to extracellular receptors and exposure to prod-
et al., 1998) and inhibits the spontaneous induction ofucts of nonviral agents. Indeed, the large number of IFN-
mRNA for the IL-121 but not the IL-122 chain during/ genes is likely to be in place to allow access to these
the culture of mouse peritoneal macrophages (Fantuzzi
et al., 2000). Although the variations may be attributed
to differences in cell populations or stimuli used, they1 Correspondence: christine_biron@brown.edu
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might be biologically consistent. Under conditions of ory CD8 T cells (Tough et al., 1996; Zhang et al., 1998)
at early times following viral infections.high concentrations of IFN-/, inhibition of IL-12 pro-
duction would be dominant because expression of the IFN- Expression
Culture studies with human T cell populations providedreceptor would not have a biological consequence if no
ligand were available to engage it. On the other hand, the first indications that type 1 IFN could upregulate
IFN- expression (Brinkmann et al., 1993). IFN-/medi-induction of a high-affinity receptor for IL-12 by either
IFN-/ or IFN- might be biologically important in the ate positive effects on T cell IFN- expression following
stimulation with particular molecules, including thecontext of low concentrations of IFN-/ because there
would still be significant IL-12 production. It should be chemical analog for viral dsRNA, polyinosinic:polycyti-
dylic acid (polyI:C) (Manetti et al., 1995; Sareneva et al.,pointed out, however, that the components of the IL-12
receptor may be regulated differently from IL-12 be- 2000). The factors also work in synergy with IL-18 to
enhance IFN- production following stimulation with in-cause they have additional functions. In particular, little
is known about the induction and function of a cytokine fluenza virus (Sareneva et al., 1998). A modest IFN-
effect on IL-12 induction of IFN- has also been ob-identified as IL-23, comprised of the IL-12 p40 and a
newly identified p19 molecule. This cytokine binds to served with mouse cells in culture (Wenner et al., 1996),
and there is a more dramatic role for IFN-/ in enhanc-the IL-12R1 but not the IL-122 chain (Oppmann et al.,
2000). Thus, there are likely to be a number of conditions ing IL-12-independent CD8 T cell IFN- expression dur-
ing LCMV infections of mice (Cousens et al., 1999).under which regulation of IL-12 might diverge from regu-
lation of its receptor. STAT4 is known to promote IFN- expression in the
human and the mouse, and it has been clearly demon-NK Cell Responses
IFN-/ promote NK cell-mediated cytotoxicity in cul- strated that type 1 IFN can activate STAT4 in the human
(Cho et al., 1996; Rogge et al., 1998). However, a mini-ture and in vivo (Biron et al., 1999). Remarkably, expo-
sure to these factors also is associated with NK cell satellite insertion into mouse STAT2 severely impairs
STAT4 activation in this species (Farrar et al., 2000).blastogenesis and proliferation but not IFN- expression
in vivo. In the context of a viral infection inducing both Thus, there is a readily accessible and potent pathway
from IFN-/ to IFN- expression in the human that doesIFN-/ and IL-12 in the mouse, murine cytomegalovirus
(MCMV), there is a clear dichotomy of function with not appear to be operational in the mouse.
Nevertheless, the complexities of IFN-/ signaling inenhanced cytotoxicity and blastogenesis dependent
upon IFN-/ but IFN- induction dependent upon IL- a physiologic context are only superficially understood.
STAT4 may not be the only pathway to IFN- expression12 (Orange and Biron, 1996). The IFN-/ cytokines also
block NK cell responsiveness to IL-12 for IFN- produc- in either the human or the mouse. As one example,
although stimulation through the T cell receptor for anti-tion (Nguyen et al., 2000). The effect on IL-12 respon-
siveness is dependent upon the presence of STAT1 and gen for CD4 T cell IFN- expression requires STAT4,
equivalent stimulation of CD8 T cell IFN- responsesoccurs despite expression of both IL-12 receptor con-
stituents. Basal and IFN-/ induction of NK cell cyto- does not (Carter and Murphy, 1999). Thus, there are
STAT4-independent pathways to IFN- expression. Thetoxicity is dependent upon STAT1 (Lee et al., 2000).
Remarkably, the STAT1-dependent effects on NK cell STAT4-dependent pathway may be a minor player in
the context of other more dominant pathways elicitedlytic function occur even though the mRNA levels for
a number of molecules involved in the activation and under challenge conditions. In this regard, it is interest-
ing to note the recently described negative effects ofdelivery of lytic function, i.e., perforin, granzyme A, gran-
zyme B, DAP10, and DAP12, are not reduced. These STAT1. In addition to playing a positive role in associa-
tion with STAT2 for gene activation in response to typeresults suggest that there may be STAT1-independent
expression of certain components of the lytic machinery 1 IFN, STAT1 homodimers are major intermediaries for
signaling from the IFN- receptor (Biron and Sen, 2001).but that expression of other key elements in the killing
pathway must be STAT1 dependent. Because STAT1 is STAT1 has been recently shown to negatively regulate
a number of effects including early NK and T cell IFN-required for the induction of NK cell cytotoxicity and is
contributing to the induction of an IL-12 refractory state expression in response to type 1 IFN exposure in the
mouse (Nguyen et al., 2000) and c-myc expression inin NK cells, the effects may be linked.
IL-15 Expression response to IFN- in the human (Ramana et al., 2000).
These studies suggest that the effects of cytokine expo-IL-15 can be a product of nonlymphoid populations at
early times following stimulation or challenge (Fehniger sure may vary greatly depending upon the ratio of signal-
ing molecules expressed in the cell cytoplasm. Further-and Caligiuri, 2001). The high-affinity receptor for IL-15
utilizes the  and  chains of the IL-2 receptor along more, if the negative regulatory effects of STAT1 are
dominant in both species, IFN-/ activation of STAT4with a unique  chain. Although there is some debate
about the efficacy of type 1 IFNs as compared to other might only occur, even within human cells, if the levels
of STAT1 are downregulated.stimuli, there is growing evidence that IFN-/ or their
inducers can elicit expression of IL-15 at least at the Expression by and Regulation of DCs
IFN-/ have the potential to indirectly influence adap-mRNA level in mouse cell populations (Zhang et al.,
1998; Durbin et al., 2000) and at both the mRNA and tive immune responses by modifying maturation of DCs,
e.g., drive DC1 populations promoting Th1, as comparedprotein level in human DCs derived from peripheral
blood monocytes cultured in type 1 IFN and GM-CSF to DC2 populations promoting Th2, CD4 T cell response.
Alternatively, if the cytokines are expressed by the DCs(Santini et al., 2000). This immunoregulatory effect of
IFN-/ has been proposed to contribute to the induc- themselves, they might directly influence the develop-
ment of T cells responding to antigen presented by thesetion of NK cell proliferation (Biron et al., 1999) and mem-
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Figure 1. A Model for the Effects Mediated by IFN-/ in the Context of Low- and High-Level Expression
The pathways proposed are based on the literature reviewed. The reader should consult the Integration and Summary section of the text for
a discussion.
cells. Type 1 IFN are poor inducers of MHC class II but infections, influenza virus infections, CD40L, and polyI:C.
By comparison to the others, CD40L is a modest inducerdo enhance MHC class I expression. IFN-/ do induce
expression of MHC class I molecules by human DCs, of type 1 IFN but a good inducer of IL-12 p70 (Cella et
al., 1996, 1999b). Certain nonviral products such as LPSbut stimulation with influenza virus or polyI:C is more
profound, with virus infection resulting in sustained ex- from Gram-negative bacteria can also induce type 1 IFN
production by DC. In the case of the response to HSV,pression of class I molecules presenting viral peptides
(Cella et al., 1999b). Exposure to IFN-/ may induce the mannose receptor on the surface of DCs appears
to play an important role in induction of IFN- expressionDC expression of the costimulatory molecules used for
communication with T cells during activation, i.e., CD80, (Milone and Fitzgerald-Bocarsly, 1998). In the case of
the response to polyI:C, the receptor for IFN inductionCD83, CD86, and/or CD40 (Gallucci et al., 1999; Ito et
al., 2001; Santini et al., 2000). Interestingly, however, may be protein kinase R (PKR) expressed in the cell
cytoplasm (Cella et al., 1999b; Kumar et al., 1994). DCthe responses of freshly isolated CD11c and CD11c
human peripheral blood DCs are different with IFN- populations derived in the context of type 1 IFN, viral
infections, and/or polyI:C appear to be potent inducersonly significantly inducing expression of costimulatory
molecules on the former (Ito et al., 2001). Moreover, the of human CD4 Th1 type responses with high levels of
IFN- production (Cella et al., 1999a, 1999b; Ito et al.,effects of adding IFN- to DC populations derived in
culture from human blood monocytes are much less 2001). Surprisingly little has been done characterizing
the consequences of DC maturation in the context ofdramatic than those elicited by exposure to influenza
virus or polyI:C (Cella et al., 1999b). IFN- does induce type 1 IFNs and/or DC expression of these cytokines
for CD8 T cell responses. IFN- pretreatments do inhibitDC expression of an antiviral protein, Mx, and increases
resistance to influenza virus infection (Cella et al., the dramatic proliferative stimulation of a viral peptide-
specific and MHC class I-restricted T cell clone, by im-1999b).
If appropriately activated, human DCs can produce mature DCs exposed to influenza virus (Cella et al.,
1999b). The IFN-/ effects on antigen presentation andhigh levels of type 1 IFN (Cella et al., 1999a, 1999b; Siegal
et al., 1999). A variety of stimuli have been examined and T cell stimulation are not yet clear, however, because
the treatment also renders the cells resistant to infectionshown to be active, including herpes simplex virus (HSV)
Immunity
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